Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1196-1203

  Errami, Mounir ^a   Galindo, Cristi L ^a   Tassa, Amina T ^a   DiMaio, John M ^b   Hill, Joseph A ^b   Garner, Harold R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GELATINASE B; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR IIA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SURGERY; ARTICLE; BODY WEIGHT; CELL FATE; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; AORTA; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DOXYCYCLINE; ISOPROTERENOL; MALE; MICE; MICE, INBRED C57BL;

EID: 40849134186     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.133975     Document Type: Article

References (41)

1. Abeles D, Kwei S, Stavrakis G, Zhang Y, Wang ET, and Garcia-Cardena G (2006) Gene expression changes evoked in a venous segment exposed to arterial flow. J Vasc Surg 44:863-870.
2. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8:35-40.
3. Chancey AL, Brower GL, Peterson JT, and Janicki JS (2002) Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105:1983-1988.
4. Chen Z, Chua CC, Ho YS, Hamdy RC, and Chua BH (2001) Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 280:H2313-H2320.
5. 1 cells. J Cell Biochem 102:1190-1201.
6. Czarnowski D, Wojcik B, Langfort J, and Gorski J (1996) 5′-Nucleotidase and adenosine deaminase activities in hypertrophied rat heart: the effect of tachycardia. Rocz Akad Med Bialymst 41:334-340.
7. Davies JE, Berger Z, and Rubinsztein DC (2006) Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int J Biochem Cell Biol 38:1457-1462.
8. Fard A, Wang CY, Takuma S, Skopicki HA, Pinsky DJ, Di Tullio MR, and Homma S (2000) Noninvasive assessment and necropsy validation of changes in left ventricular mass in ascending aortic banded mice. J Am Soc Echocardiogr 13:582-587.
9. 2-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load. Hypertension 37:1222-1228.
10. Frey N and Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45-79.
11. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, and Sorsa T (1998) Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12:12-26.
12. Grenier D, Plamondon P, Sorsa T, Lee HM, McNamara T, Ramamurthy NS, Golub LM, Teronen O, and Mayrand D (2002) Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. J Periodontol 73:79-85.
13. Griffin MO, Jinno M, Miles LA, and Villarreal FJ (2005) Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. Mol Cell Biochem 270:1-11.
14. Gutstein DE, Morley GE, and Fishman GI (2001) Conditional gene targeting of connexin43: exploring the consequences of gap junction remodeling in the heart. Cell Commun Adhes 8:345-348.
15. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, and Weiss RM (2000) Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101:2863-2869.
16. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, and Takeshita A (2004) Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64:526-535.
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
18. Kannel WB, Gordon T, and Offutt D (1969) Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 71:89-105.
19. Kim H, Luo L, Pflugfelder SC, and Li D (2005) Doxycycline inhibits TGF-β1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. Invest Ophthalmol Vis Sci 46:840-848.
20. Kostin S, Dammer S, Hein S, Klovekorn WP, Bauer EP, and Schaper J (2004) Connexin 43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis. Cardiovasc Res 62:426-436.
21. Li D, Chen Z, Song XJ, Luo L, and Pflugfelder SC (2004) Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 45:4302-4311.
22. Li WG, Zaheer A, Coppey L, and Oskarsson HJ (1998) Activation of JNK in the remote myocardium after large myocardial infarction in rats. Biochem Biophys Res Commun 246:816-820.
23. T method. Methods 25:402-408.
24. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, and Yusuf S (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615-1621.
25. Miura S, Ohno I, Suzuki J, Suzuki K, Okada S, Okuyama A, Nawata J, Ikeda J, and Shirato K (2003) Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by β-adrenergic stimulation in rats. J Cardiovasc Pharmacol 42:174-181.
26. Ohki R, Yamamoto K, Ueno S, Mano H, Misawa Y, Fuse K, Ikeda U, and Shimada K (2004) Transcriptional profile of genes induced in human atrial myocardium with pressure overload. Int J Cardiol 96:381-387.
27. Pellieux C, Sauthier T, Aubert JF, Brunner HR, and Pedrazzini T (2000) Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. J Hypertens 18:1307-1317.
28. Petrich BG and Wang Y (2004) Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med 14:50-55.
29. Petrich BG, Eloff BC, Lerner DL, Kovacs A, Saffitz JE, Rosenbaum DS, and Wang Y (2004) Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. J Biol Chem 279:15330-15338.
30. Raskoff WJ, Goldman S, and Cohn K (1976) The "athletic heart": prevalence and physiological significance of left ventricular enlargement in distance runners. J Am Med Assoc 236:158-162.
31. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, and Berrebi-Bertrand I (2001) EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 33:1589-1606.
32. Rosenkranz S (2004) TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63:423-432.
33. Soini Y, Satta J, Maatta M, and Autio-Harmainen H (2001) Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 194:225-231.
34. Spinale FG, Coker ML, Bond BR, and Zellner JL (2000) Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46:225-238.
35. Tachibana H, Perrino C, Takaoka H, Davis RJ, Naga Prasad SV, and Rockman HA (2006) JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem Biophys Res Commun 343:1060-1066.
36. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, and Covell J (2003) Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108:1487-1492.
37. Wainwright CL (2004) Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion. Curr Opin Pharmacol 4:132-138.
38. Watkins SJ, Jonker L, and Arthur HM (2006) A direct interaction between TGFβ activated kinase 1 and the TGFβ type II receptor: implications for TGFβ signalling and cardiac hypertrophy. Cardiovasc Res 69:432-439.
39. Wren JD, Bekeredjian R, Stewart JA, Shohet RV, and Garner HR (2004) Knowledge discovery by automated identification and ranking of implicit relationships. Bioinformatics 20:389-398.
40. Yu L, Hebert MC, and Zhang YE (2002) TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 21:3749-3759.
41. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, and Schneider MD (2000) TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6:556-563.